INmune Bio, Inc.
INmune Bio, Inc. (INMB) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
inmb · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for INmune Bio, Inc. (INMB) measures how much investors pay for each dollar of the company's trailing earnings. INMB's current PE ratio of N/A is calculated by dividing its stock price of $1.24 by its TTM earnings per share of -$1.56.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2015 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
INmune Bio, Inc.You INMB | $33M | N/A | — | -$1.56 |
 Aligos Therapeutics, Inc. ALGS | $31M | N/A | — | -$2.45 |
 Barinthus Biotherapeutics plc BRNS | $29M | N/A | — | -$1.64 |
 CEL-SCI Corporation CVM | $9M | N/A | — | -$6.27 |
 FibroGen, Inc. FGEN | $37M | 0.19x | — | $45.38 |
 Mersana Therapeutics, Inc. MRSN | $145M | N/A | — | -$14.12 |
 OnKure Therapeutics, Inc. OKUR | $60M | N/A | — | -$4.40 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.73 | — | |
2024-12-31 FY2024 | — | $-2.11 | — | |
2023-12-31 FY2023 | — | $-1.67 | — | |
2022-12-31 FY2022 | — | $-1.52 | — | |
2021-12-31 FY2021 | — | $-1.88 | — | |
2020-12-31 FY2020 | — | $-1.01 | — | |
2019-12-31 FY2019 | — | $-0.75 | — | |
2018-12-31 FY2018 | — | $-1.11 | — | |
2017-12-31 FY2017 | — | $-0.07 | — | |
2016-12-31 FY2016 | — | $-0.05 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for INmune Bio, Inc. (INMB) measures how much investors pay for each dollar of the company's trailing earnings. INMB's current PE ratio of N/A is calculated by dividing its stock price of $1.24 by its TTM earnings per share of -$1.56.
Frequently asked questions
INMB pe ratio · 6 questionsINMB's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.24 and TTM EPS of -$1.56. Data sourced from Financial Modeling Prep via INMB's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · INmune Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09